SIBN (SI-BONE) COGS-to-Revenue : 0.20 (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is SI-BONE COGS-to-Revenue?

SI-BONE's Cost of Goods Sold for the three months ended in Mar. 2025 was $9.6 Mil. Its Revenue for the three months ended in Mar. 2025 was $47.3 Mil.

SI-BONE's COGS to Revenue for the three months ended in Mar. 2025 was 0.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SI-BONE's Gross Margin % for the three months ended in Mar. 2025 was 79.71%.

SI-BONE COGS-to-Revenue Historical Data

The historical data trend for SI-BONE's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE COGS-to-Revenue Chart

SI-BONE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.12

0.15

0.21

SI-BONE Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.21	0.21	0.21	0.21	0.20

SI-BONE COGS-to-Revenue Calculation

SI-BONE's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	35.057	/	167.178
	=	0.21

SI-BONE's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9.595	/	47.29
	=	0.20

SI-BONE (NAS:SIBN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SI-BONE's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	9.595 / 47.29
	=	79.71 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

SI-BONE COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of SI-BONE's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

SI-BONE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

2K3:Germany

Address

471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050

Website

https://www.si-bone.com

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Executives

Anshul Maheshwari	officer: Chief Financial Officer	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Anthony J Recupero	officer: Chief Commercial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael A Pisetsky	officer: GC & Chief Compliance Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis	officer: Chief Financial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn	director, officer: Chairman, President & CEO	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Davis Timothy E Jr	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh	director	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Skyline Venture Partners V Lp	10 percent owner	525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling	officer: CMO and VP, Medical Affairs	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby	officer: Chief Technology Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan	director	452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451